BPC-157: Synthetic Pentadecapeptide Research Overview

BPC-157 — short for Body Protection Compound 157 — is a synthetic pentadecapeptide consisting of 15 amino acids. The sequence corresponds to a fragment of a larger protective protein originally identified within human gastric juice by Sikiric and colleagues in the 1990s.^[1] The full primary structure is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.

The 'BPC' designation refers to the broader class of body protection compounds isolated from gastric tissue. The numerical suffix identifies this specific 15-residue sequence within the larger BPC fragment. BPC-157 has attracted ongoing interest as a model compound for studying protective signaling pathways because of one unusual property: unlike most peptides, it has demonstrated remarkable in vitro stability in human gastric juice, surviving for extended periods without significant proteolytic cleavage.^[1][2]

Across the preclinical literature, BPC-157 has been examined in models of tissue signaling, vascular pathway activation, and growth factor receptor research. The compound is studied exclusively as a research material in controlled laboratory environments and has not been approved by the FDA for any human therapeutic, diagnostic, or medical purpose.

BPC-157's primary structure carries several features worth noting from a structural chemistry perspective:

• Sequence (one-letter code): GEPPPGKPADDAGLV

• Sequence (three-letter): Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

• Empirical formula: C₆₂H₉₈N₁₆O₂₂

• Average molecular weight: approximately 1,419.5 Da

• Residue count: 15 amino acids

• Proline content: 4 of 15 residues — a notably high proportion

The high proline content is structurally significant. Proline's rigid pyrrolidine ring restricts backbone flexibility, contributing to defined conformational states and reducing accessibility for many proteolytic enzymes. This is one of the leading hypotheses for the compound's observed enzymatic stability in gastric juice in vitro.^[2]

BPC-157 contains no cysteine residues, so it cannot form disulfide bonds. This simplifies handling — there are no oxidation concerns of the kind that complicate work with disulfide-containing peptides — but also means stabilization comes entirely from the backbone topology rather than tertiary stabilization.

The N-terminal glycine and C-terminal valine are typical of synthetic peptides produced by solid-phase peptide synthesis (SPPS). Most research-grade BPC-157 is supplied as a lyophilized powder, typically in 5mg, 10mg, or 20mg vials, sealed under inert atmosphere to preserve integrity until reconstitution.

Multiple preclinical investigations have examined BPC-157's effects on cellular signaling pathways. The published research has focused on several pathway families, each studied independently in controlled experimental systems.

Several preclinical studies have examined BPC-157's interaction with the nitric oxide signaling pathway, particularly with endothelial nitric oxide synthase (eNOS) regulation. Sikiric and colleagues described modulation of NO production in vascular models as a candidate mechanism underlying the compound's broader effects.^[3]

This pathway is of interest in vascular research because NO is a central signaling molecule for endothelial function, vasodilation, and angiogenesis. The reported BPC-157 effects in this domain are model-dependent and remain under active investigation.

Vascular endothelial growth factor (VEGF) receptor activation has been examined in BPC-157 research as a potential mechanism for the angiogenesis-related effects observed in preclinical wound and tissue models.^[4] Studies in this category typically use cell culture systems exposing endothelial cells or fibroblast lines to the compound, then assay for VEGF receptor 2 (VEGFR2) activation or downstream signaling markers.

A separate body of literature has examined BPC-157 effects on dopaminergic and serotonergic neurotransmission in preclinical rodent models.^[5] These studies sit within neuropharmacology research and are notable for being conducted in vivo (in animal models) rather than purely in vitro. As with all such work, findings in animal models do not establish efficacy or safety in humans.

The published preclinical literature on BPC-157 spans several distinct research domains. Below is a non-exhaustive summary of the categories under which the compound has been studied.

Studies have examined the effects of BPC-157 on tendon-derived fibroblast cell lines and rodent tendon injury models. Outcomes assessed include cell outgrowth rate, collagen expression profiles, and tensile strength recovery in animal models.^[6] These investigations are conducted exclusively in preclinical systems and do not extrapolate to human therapeutic use.

Given its origin from a gastric protein, BPC-157 has been studied extensively in preclinical gastrointestinal models. Research has examined the compound in rodent models of induced gastric injury, intestinal anastomosis, and esophagitis.^[7] The gastric-juice stability observation that initially drew interest to the compound was made in this research context.

BPC-157 has been examined in preclinical vascular models — endothelial cell migration assays, in vitro tube formation, and in vivo wound healing models in rodents. The reported angiogenesis-related effects connect with the VEGF receptor and NO pathway research described above.^[4][8]

A smaller body of literature has examined BPC-157 in rodent models of bone defect repair and osteogenesis. As with all preclinical bone research, the findings are interpreted within the controlled-experiment framework and do not establish clinical applicability.^[9]

BPC-157 is most commonly supplied as a lyophilized (freeze-dried) powder. The compound's structural properties — high proline content, no disulfide bonds — make it relatively stable compared to many synthetic peptides. However, proper handling remains important for reliable research outcomes.

Lyophilized BPC-157 is typically stored at −20°C or colder for long-term preservation. Short-term storage at 4°C is acceptable for actively used material. Once reconstituted into aqueous solution, the compound is generally less stable and is usually stored at 4°C with use within several weeks, depending on solvent and concentration.

Bacteriostatic water (0.9% benzyl alcohol) is the most common reconstitution solvent for laboratory research preparations. Sterile water is also used. Some preclinical research protocols call for slightly acidic conditions — dilute acetic acid solution — for specific assays, though plain aqueous solvents are sufficient for most work. Reconstitution should be performed gently, allowing the solvent to flow down the vial wall rather than directly onto the peptide pellet, and the vial should be swirled gently rather than shaken to minimize foaming.

Independent quality verification typically includes HPLC for purity quantification (target ≥99%), mass spectrometry for identity confirmation, and endotoxin testing for sterility. Each batch of Instant Peptides BPC-157 ships with a full Certificate of Analysis documenting these results — accessible via our Lab Tests page.

Instant Peptides supplies BPC-157 as a synthetic reference compound for laboratory research applications. Material is sold exclusively to qualified research professionals, scientific institutions, and biological supply customers. Not for human or animal consumption, diagnostic, or therapeutic use.

View the product page for available sizes, current pricing, and the Certificate of Analysis for the active batch.